Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 112,095 | 91,386 | 93,986 | 105,109 | 173,063 |
| Marketable Securities | 9,711 | 36,994 | 64,050 | 91,857 | 64,698 |
| Receivables | 33,082 | 19,703 | 19,649 | 19,638 | 20,302 |
| Inventories | 16,464 | 8,341 | 7,128 | 7,590 | 9,227 |
| TOTAL | $186,024 | $168,546 | $196,868 | $237,177 | $276,135 |
| Non-Current Assets | |||||
| PPE Net | 637 | 695 | 688 | 627 | 655 |
| Investments And Advances | 0 | 380 | 4,632 | 4,514 | 5,022 |
| Other Non-Current Assets | 13,794 | 15,425 | 6,529 | 5,300 | 3,899 |
| TOTAL | $14,431 | $16,500 | $11,849 | $10,441 | $9,576 |
| Total Assets | $200,455 | $185,046 | $208,717 | $247,618 | $285,711 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 27,717 | 26,173 | 30,962 | 30,322 | 27,431 |
| Accrued Expenses | 13,516 | 11,114 | 11,646 | 6,967 | 10,570 |
| Other current liabilities | 5,185 | 4,957 | 4,940 | 4,711 | 7,948 |
| TOTAL | $46,418 | $42,244 | $47,548 | $42,000 | $45,949 |
| Non-Current Liabilities | |||||
| Long Term Debt | 122,210 | 122,111 | 122,508 | 122,108 | 121,734 |
| Other Non-Current Liabilities | 137,301 | 136,099 | 132,037 | 129,968 | 126,831 |
| TOTAL | $259,511 | $258,210 | $254,545 | $252,076 | $248,565 |
| Total Liabilities | $305,929 | $300,454 | $302,093 | $294,076 | $294,514 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 48,682 | 46,809 | 46,264 | 46,107 | 46,094 |
| Common Shares | 133 | 128 | 126 | 126 | 115 |
| Retained earnings | -959,716 | -933,352 | -900,005 | -850,065 | -806,222 |
| Other shareholders' equity | 19 | 23 | 6 | 14 | 56 |
| TOTAL | $-105,474 | $-115,408 | $-93,376 | $-46,458 | $-8,803 |
| Total Liabilities And Equity | $200,455 | $185,046 | $208,717 | $247,618 | $285,711 |